Haukeland University Hospital
helse-bergen.noTotal trials
279
Active
80
Phase 3
15
Total enrollment
93,959
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 34 of 34 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | 5 | ||
| Nirmatrelvir/ritonavir | — | — | — | — | — | 1 | |
| Cyclophosphamide and ATG | — | — | — | — | — | 1 | |
| Alemtuzumab | — | — | — | — | — | 1 | |
| Cladribine Pill | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | — | 3 | |
| Sirolimus 1 mg Oral | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Neoadjuvant tamoxifen + goserelin | — | — | — | — | — | 1 | |
| Neoadjuvant letrozole | — | — | — | — | — | 1 | |
| Neoadjuvant endocrine therapy + palbociclib | — | — | — | — | — | 1 | |
| Neoadjuvant docetaxel + cyclophosphamide | — | — | — | — | — | 1 | |
| Neoadjuvant docetaxel | — | — | — | — | — | 1 | |
| Neoadjuvant docetaxel + trastuzumab + pertuzumab | — | — | — | — | — | 1 | |
| Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab | — | — | — | — | — | 1 | |
| Neoadjuvant olaparib | — | — | — | — | — | 1 | |
| Neoadjuvant cyclophosphamide | — | — | — | — | — | 1 | |
| Adjuvant trastuzumab | — | — | — | — | — | 1 | |
| Adjuvant letrozole | — | — | — | — | — | 1 | |
| Adjuvant tamoxifen + goserelin | — | — | — | — | — | 1 | |
| Adjuvant palbociclib | — | — | — | — | — | 1 | |
| Adjuvant Epirubicin+ Cyclophosphamide | — | — | — | — | — | 1 | |
| Hydroxyurea, Hydroxycarbamide | — | — | — | — | — | 1 | |
| Valproic acid | — | — | — | — | — | 1 | |
| 6-Mercaptopurine | — | — | — | — | — | 1 | |
| Psychotherapy as usual combined with single dose normal gut microbiota | — | — | — | — | — | 1 | |
| Nicotine patch | — | — | — | — | — | 1 | |
| Nicotine gum | — | — | — | — | — | 1 | |
| Nicotine lozenge | — | — | — | — | — | 1 | |
| Comprehensive molecular profiling | — | — | — | — | — | 1 | |
| GLP-1 | — | — | — | — | — | 1 |
Next readouts
- 2020-06-01
- 2020-12
- 2023-10-31
- 2024-05
- 2025-03-24
- 2025-08-14
- 2025-09-09
- 2025-11-30
- 2026-11-21
- 2027-11-05
Top conditions
- Amyotrophic Lateral Sclerosis5
- Obesity5
- Ischemic Stroke5
- Cognitive Impairment4
- Multiple Sclerosis4
- Chronic Fatigue Syndrome4
- Parkinson Disease4
- Quality of Life4
Frequently asked questions about Haukeland University Hospital
- How many clinical trials does Haukeland University Hospital have on ClinicalTrials.gov?
- Haukeland University Hospital is listed as the lead sponsor on 279 clinical trials in ClinicalTrials.gov, 80 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Haukeland University Hospital's trials are in Phase 3?
- 15 of Haukeland University Hospital's trials are in Phase 3, spread across 34 active drug programs.
- What therapeutic areas does Haukeland University Hospital focus on?
- Haukeland University Hospital's most-studied conditions on ClinicalTrials.gov are Amyotrophic Lateral Sclerosis, Obesity, Ischemic Stroke, Cognitive Impairment, Multiple Sclerosis.
- When are Haukeland University Hospital's next clinical trial readouts?
- Haukeland University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial”, expected around 2020-06-01.